A vaccine that blocks the effects of fentanyl — including overdose — will enter human trials in the coming months, perhaps leading the way to the first-ever proactive treatment for opioid use disorder.
The initial trials will focus on assessing the safety of the vaccine, which was initially developed with funding from the U.S. Department of Defense. The shot was previously tested in rats and showed promising results. Now, it's been licensed by startup ARMR Sciences, which will begin enrolling patients for Phase I clinical trials in the Netherlands in 2026, starting in either January or February.
